一个具有改善性炎症微环境的生物模拟纳米球片用于阿尔茨海默病治疗
Yanyue Wu1,2,3, Jun Yang1,2,3, Yiwan Geng1,2,3
1State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
Advanced healthcare materials
|November 7, 2023
概括
这项研究引入了一个生物模拟纳米小球来治疗阿尔茨海默病 (AD) 通过准粉样β oligomers 和神经炎症. 纳米小球有效地穿透了血脑屏障,为AD提供了一个有前途的新治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 粉样蛋白-β (Aβ) 寡合体先于斑块形成,并导致阿尔茨海默病 (AD) 中的神经元损伤和神经炎症.
- 血脑屏障 (BBB) 和药物限制阻碍了有效的AD疗法.
- 针对Aβ寡合体和神经炎症,为阿尔茨海默病提供了一个有前途的治疗途径.
研究的目的:
- 开发一种生物模拟纳米球体系统,同时消除Aβ寡合体,缓解AD中的神经炎症.
- 为了克服BBB透的挑战,并改善药物输送到大脑AD治疗.
- 在AD的细胞模型中评估生物模拟纳米小球的疗效和机制.
主要方法:
- 生物模拟纳米球体 (PBACR@NRs/SA) 的开发,灵感来自狂犬病病毒的特性,采用氧化铁纳米棒进行BBB透.
- 迷酸和小干扰RNA的连续释放准NF-κB,由微环境触发.
- 与非仿生系统相比,评估纳米球体内化通路,反应性氧物种 (ROS) 生产和神经元中的线粒体裂变.
主要成果:
- 生物模拟纳米子弹证明了有效的BBB透.
- 治疗剂的顺序释放成功地减少了神经炎症和Aβ寡合体相关的损伤.
- 与非仿生系统相比,仿生纳米子弹在神经元中减少了ROS的产生和线粒体裂变,这是由于其不太依赖于洞穴素的内化途径.
结论:
- 开发的生物模拟纳米小球体是阿尔茨海默病的有希望的治疗候选者,它既可以治疗Aβ寡聚体,也可以治疗神经炎症.
- 这种纳米泡平台为治疗需要BBB透的其他神经疾病提供了潜在的策略.
- 这项研究强调了病毒启发的纳米载体在增强脑疾病治疗中的潜力.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.5K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.0K
相关概念视频
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
